In patients with anti-LGI1/CASPR2-encephalitis, treatment studies should focus on specific symptoms, e.g. seizures and cognition (7, 17), or use more distinctive clinical scores like the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) (18). This evidence concerns the gene LGI1 and autoimmune encephalitis.